Drugs / Surzebiclimab
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03744468 | Nov 2018 → Feb 2025 | head and neck squamous cell carcinoma | BeiGene | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05909904 | Aug 2023 → Jun 2025 overdue | head and neck squamous cell carcinoma | BeiGene | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04164199 | Dec 2019 → May 2026 | cancer | BeOne Medicines | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Surzebiclimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03744468 ↗ |
| Known as | BGB-A425 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05909904 ↗ |
| Action | Inhibit | “surzebiclimab (anti TIM-3)” NCT03744468 ↗ |
| Modality | Monoclonal antibody | — CHEMBL4594464 ↗ |
| Route | Intravenous | “surzebiclimab 2 mg intravenous (IV) infusion on day 1 of each cycle” NCT03744468 ↗ |